Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 December;47(4) > The Quarterly Journal of Nuclear Medicine 2003 December;47(4):349-61

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

  USE OF RADIOLABELLED PEPTIDES FOR SCINTIGRAPHY IN NON-ONCOLOGIC DISEASES 

The Quarterly Journal of Nuclear Medicine 2003 December;47(4):349-61

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

The role of labeled Annexin A5 in imaging of programmed cell death. From animal to clinical imaging

Kietselaer B. L. J. H. 1, Hofstra L. 1, Dumont E. A. W. 1, Reutelingsperger C. P. M. 2, Heidendal G. A. K. 3

1 Department of Cardiology University Hospital of Maastricht, Maastricht, The Netherlands 2 Department of Biochemistry University of Maastricht, Maastricht, The Netherlands 3 Department of Nuclear Medicine University Hospital of Maastricht, Maastricht, The Netherlands


PDF


Programmed ­cell ­death ­plays a crit­i­cal ­role in embryo­lo­gy, homeo­sta­sis and dis­ease. However, ­until recent­ly no non-inva­sive imag­ing modal­ity has ­been ­able to vis­u­al­ize ­this pro­cess direct­ly. Annexin A5 ­binds to ­cells under­go­ing pro­grammed ­cell ­death. When label­ing ­this pro­tein, Annexin A5 ­becomes a ­tool for the detec­tion of pro­grammed ­cell ­death in ­vitro and in ­vivo. Labeled Annexin A5 has ena­bled our ­group and oth­ers to ­detect pro­grammed ­cell ­death non-inva­sive­ly in ani­mals and ­patients. This ­review ­will high­light the devel­op­ment of ­this imag­ing modal­ity in cel­lu­lar and ani­mal mod­els. Furthermore, we ­will dis­cuss Annexin A5 imag­ing in ­human dis­ease. We ­will ­focus on the clin­i­cal appli­ca­tions and ­their rel­e­vance, lim­i­ta­tions and ­future per­spec­tives of non-inva­sive imag­ing of pro­grammed ­cell ­death ­using ­labeled Annexin A5.

top of page